In the hyperphagic leptin-receptor-deficient BKS db/db mice, an experimental model resembling human diabesity, we observed that the administration of semaglutide for 11 weeks led to a decrease in average body weight, which was consistent with the reported effect of this drug in obesity and diabetes contexts [25]. Here, LEPR is linked to obesity disorder.